Lilly(Eli) & Company
NYSE: LLY
$921.49
+$6.45 (+0.7%)
Closing Price on September 20, 2024
LLY Articles
If there is one thing that the pharmaceutical industry tries to shy away from it is the controversy over the costs of some of the drugs on the market today.
Published:
Thursday's top analyst upgrades, downgrades include Apple, Barrick Gold, Corning, Groupon, Peabody Energy and SolarCity.
Published:
In a new research report, the SunTrust Robinson Humphrey team highlights the top pharmaceutical stocks to buy for 2015.
Published:
Thursday's top analyst upgrades and downgrades from 24/7 Wall St. include ARIAD Pharmaceuticals, FedEx, Genpact, Suncor Energy, Travelers and UPS.
Published:
ThinkstockStocks have enjoyed yet another wonderful year in 2014, and the bull market is now more than five and a half years old. With the S&P 500 index up almost 14% year-to-date ahead of...
Published:
The data is grim: cancer is increasing. Sales of these top oncology drugs are likely to increase as well.
Published:
These are the top analyst upgrades, downgrades and initiations from Wall Street firms for Thursday, July 31, 2014. They include Cliffs Natural Resources, Eli Lilly, Enphase Energy, Lululemon,...
Published:
These are the top analyst upgrades, downgrades and initiations from Wall Street firms for Tuesday, July 2, 2014. They include Alcatel-Lucent, Apple, FireEye, JDSU Uniphase and solar stocks.
Published:
ThinkstockDividend payments by S&P 500 companies reached an all-time high last year, totaling some $330.8 billion, according to FactSet. As of this March, 418 of the 500 companies in the index...
Published:
Last Updated:
The NYSE Arca Biotechnology Index fell nearly 9% between a peak on Jan. 22 and a low on Feb. 5. It jumped 23% over the next three weeks, and then gave it all back and then some through April 15.
Published:
UPS reported first-quarter 2014 results before markets opened Thursday, and no surprise, winter weather was its theme of the day. And no surprise either that shares slipped after the opening bell.
Published:
Eli Lilly reported disappointing first-quarter 2014 results before markets opened Thursday, due in part to the impact of U.S. patent expirations for Cymbalta and Evista. Shares were up in premarket...
Published:
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Thursday, April 3, 2014. They include Apple, Intel, Chevron, Exxon, Qualcomm and Citigroup.
Published:
The chief strategist at Piper Jaffray released his report for March. It details how the second and third quarters typically behave in the mid-term years after a solid first quarter. Here are the top...
Published:
In a new research report, Cowen analysts posted a list of some of the top new datapoints cited at the Cowen 2014 Healthcare Conference by large cap pharmaceutical companies concerning upcoming events...
Published: